AspirinPlatelet Aggregation InhibitorsAnti-Inflammatory Agents, Non-SteroidalDrug Administration ScheduleAdministration, OralRadiation DosageTime FactorsDouble-Blind MethodDrug Therapy, CombinationTiclopidineLethal Dose 50Thromboxane B2Dose-Response Relationship, DrugTreatment OutcomeCyclooxygenase InhibitorsPlatelet AggregationSalicylatesRadiometryPlatelet Function TestsDose-Response Relationship, RadiationInjections, IntravenousDrug InteractionsRadiotherapy DosageBlood PlateletsDose FractionationSodium SalicylateAnticoagulantsWarfarinHemorrhageInfusions, IntravenousProspective StudiesRats, Sprague-DawleyFibrinolytic AgentsIbuprofenArea Under CurveAcetaminophenDrug ResistanceHalf-LifeRats, WistarBleeding TimeRadiotherapy Planning, Computer-AssistedTablets, Enteric-CoatedAsthma, Aspirin-InducedFollow-Up StudiesProstaglandin-Endoperoxide SynthasesCyclooxygenase 1Gastrointestinal HemorrhageDisease Models, AnimalThromboxanesRisk FactorsDipyridamoleDrug CombinationsCyclooxygenase 2 InhibitorsThrombosisPlatelet ActivationRandom AllocationAntineoplastic AgentsInjections, SubcutaneousDrug SynergismAdministration, InhalationDogsNeoplasmsLiverThromboxane A2Drug EvaluationRecurrenceGastric MucosaRadiation InjuriesBody BurdenPlacebosRelative Biological EffectivenessMyocardial InfarctionBody WeightStomach UlcerDose-Response Relationship, ImmunologicBlood PressureIndomethacinClinical Trials as TopicMetabolic Clearance RateProstaglandinsBiological AvailabilityCyclooxygenase 2Rats, Inbred StrainsRetrospective StudiesAntineoplastic Combined Chemotherapy ProtocolsInjections, IntraperitonealThermoluminescent DosimetryKidneyHeparinRisk AssessmentDinoprostoneLipoxinsRandomized Controlled Trials as TopicAnalysis of VariancePregnancyRabbitsStrokePyrazolesMice, Inbred BALB CSulfinpyrazone